February 2026 Research Update

This month added two complementary pieces about how VEXAS care is being organized and studied: a national multidisciplinary team (MDT) experience and a new randomized trial plan. Together, they show a field that is moving from individual, case-by-case decisions toward more standardized discussions and formal testing of specific medicines, even though results are still limited. The common thread is a focus on finding ways to control inflammation while reducing long-term reliance on steroids, but without claiming any one approach is best yet. [1] [2]

In the UK national MDT report, the team reviewed 42 patients discussed across 27 centers and tracked what was recommended in real-world decision-making. The MDT more often favored steroid-sparing approaches, with increased use of azacitidine and tocilizumab and less use of conventional immune-suppressing drugs, and a small number of patients were referred for stem cell transplant evaluation. This does not show which treatment works best, but it shows how expert groups are converging on certain options when weighing inflammation control, blood disease features, and risks. [1]

The PAXIS study publication is a trial protocol, meaning it explains what will be tested but does not report outcomes yet. It plans to compare two dose levels of pacritinib (a medicine that blocks signals involved in inflammation and blood cell production) versus placebo over 24 weeks, with a structured steroid taper, and then follow participants in an open-label phase. For patients, the main new information is that a placebo-controlled VEXAS trial is actively designed around practical goals like staying flare-free while on a low steroid dose, but it remains unknown whether pacritinib will meet that goal until results are published. [2]

For patients and caregivers, these studies mainly show how VEXAS care is becoming more coordinated and how new treatments are being tested more formally. The MDT experience may matter now in the sense that it documents a real-world shift toward certain steroid-sparing options and multidisciplinary decision-making, but it does not prove those options work better. The pacritinib trial may matter later if it shows clear benefits and acceptable safety, since this publication is a plan without results. What remains uncertain is which treatments work best for which VEXAS patterns, and whether trial results will match what is being done in routine care. [1] [2]

This month brought a clearer signal that people with VEXAS may have a higher overall risk of cancer compared with people who have other autoinflammatory diseases. The same study also suggested that certain VEXAS features may cluster with higher cancer risk, including relapsing polychondritis (inflammation of cartilage), the p.Met41Thr UBA1 mutation, and higher inflammation markers even outside flares. For patients, this adds to the broader picture that VEXAS is not only about inflammation symptoms, and that ongoing inflammation and specific disease subtypes may relate to longer-term risks. [3]

In an international registry comparison, VEXAS was linked to a higher overall cancer risk, with a reported relative risk of 1.93 versus the control group of other autoinflammatory diseases. The analysis also reported higher risk in people with relapsing polychondritis and in those with the p.Met41Thr UBA1 variant, and it linked higher ESR and LDH levels (blood measures that can reflect inflammation or tissue stress) with cancer risk. Because this was a registry-based observational analysis, it cannot explain why the risk is higher, but it helps identify which clinical features might matter most to study next. [3]

For patients, this evidence may matter now mainly as context for understanding the full health picture in VEXAS, rather than as an immediate change in care. The study supports the idea that cancer risk deserves attention in VEXAS research and that some subgroups may carry more risk, but it does not show that any specific monitoring plan or treatment prevents cancer. What remains uncertain is how much of the risk is driven by VEXAS itself versus related blood disorders, inflammation severity, or other factors not fully captured in registries. This work mainly adds a clearer risk signal that future studies can refine and explain. [3]

This month, several single-patient reports broadened the picture of how VEXAS can look in real life, especially around organ involvement and the mix of inflammation with blood problems. Across these cases, the pattern was a complicated course with periods of symptom improvement on targeted immune treatments, but also relapses, infections, and progression of underlying blood disease in some patients. For patients, the main value is not that these treatments are proven, but that they illustrate the range of VEXAS presentations and the kinds of complications that can shape outcomes. [4] [5] [6] [7]

Two reports highlighted severe vascular and clotting-related inflammation as part of some VEXAS courses, alongside later major complications. In one patient, symptoms improved at first with tocilizumab (an IL-6 blocking medicine) but the disease later progressed to myelodysplastic syndrome and ended with multiorgan failure. In another patient, ruxolitinib plus steroids led to only temporary stabilization, and the course later included major complications after treatment interruption during COVID-19 infection. [4] [5]

These cases also added detail about where VEXAS-related changes can be found and what organs can be involved. One early-onset case reported finding the UBA1 mutation not only in blood and bone marrow but also in cells collected from lung wash fluid, alongside recurrent lung inflammation and transfusion-dependent anemia. Another case described neutrophilic colitis (colon inflammation rich in neutrophils) with blood vessel injury on biopsy, plus muscle inflammation around the eye and jaw, with improvement reported on corticosteroids plus methotrexate. [6] [7]

For patients and caregivers, these reports may matter most for recognition and expectation-setting rather than guiding decisions, because each describes only 1 person. They reinforce that VEXAS can involve many organs (including lungs, blood vessels, muscles, and the gut) and that blood disease features such as myelodysplastic syndrome can emerge over time in some people. They also show that medicines like tocilizumab, ruxolitinib, azacitidine, steroids, and methotrexate have been tried with mixed and sometimes temporary responses, and infections were part of the course in some patients. What remains uncertain is how common these specific patterns are and which treatments reliably help, since case reports cannot separate treatment effects from an individual patient's disease path. [4] [5] [6] [7]